NASDAQ:OPTN - OptiNose Stock Price, Forecast & News

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

OptiNose Inc (NASDAQ:OPTN) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.69). The firm earned $12.40 million during the quarter, compared to the consensus estimate of $8.56 million. OptiNose had a negative return on equity of 137.60% and a negative net margin of 419.37%. View OptiNose's Earnings History.

OptiNose is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for OptiNose.

4 analysts have issued 12 month price objectives for OptiNose's shares. Their forecasts range from $20.00 to $29.00. On average, they anticipate OptiNose's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 167.7% from the stock's current price. View Analyst Price Targets for OptiNose.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptiNose.

Media headlines about OPTN stock have been trending negative this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OptiNose earned a media sentiment score of -2.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for OptiNose.

Some companies that are related to OptiNose include Madrigal Pharmaceuticals (MDGL), Corcept Therapeutics (CORT), Amneal Pharmaceuticals (AMRX), Arvinas (ARVN), Myovant Sciences (MYOV), Esperion Therapeutics (ESPR), Nabriva Therapeutics (NBRV), Innoviva (INVA), Athenex (ATNX), Constellation Pharmaceuticals (CNST), Enanta Pharmaceuticals (ENTA), Y-mAbs Therapeutics (YMAB), Wave Life Sciences (WVE), Theravance Biopharma (TBPH) and BELLUS Health (BLUSF).

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Idera Pharmaceuticals (IDRA), Proteostasis Therapeutics (PTI), Syndax Pharmaceuticals (SNDX), Coherus Biosciences (CHRS), Clearside Biomedical (CLSD), Arcos Dorados (ARCO), Resonant (RESN), OrganiGram (OGI), SVB Financial Group (SIVB) and Stemline Therapeutics (STML).

(OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

OptiNose's stock is owned by a number of of institutional and retail investors. Top institutional investors include Rice Hall James & Associates LLC (3.33%), Massachusetts Financial Services Co. MA (2.49%), Tamarack Advisers LP (1.63%), Kornitzer Capital Management Inc. KS (1.31%), Wildcat Capital Management LLC (1.25%) and State Street Corp (1.05%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Peter K Miller, Robert P O'neil, Sriram Venkataraman and Thomas Edward Gibbs. View Institutional Ownership Trends for OptiNose.

OPTN stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Rice Hall James & Associates LLC and Barclays PLC. Company insiders that have sold OptiNose company stock in the last year include Avista Capital Partners Ii Gp, and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose.

OPTN stock was bought by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, Wildcat Capital Management LLC, Massachusetts Financial Services Co. MA, Millennium Management LLC, State Street Corp, Tower Research Capital LLC TRC and Squarepoint Ops LLC. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Peter K Miller, Robert P O'neil and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose.

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OPTN stock can currently be purchased for approximately $9.34.

OptiNose has a market capitalization of $388.36 million and generates $7.07 million in revenue each year. The company earns $-106,660,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. OptiNose employs 102 workers across the globe.View Additional Information About OptiNose.

The official website for OptiNose is http://www.optinose.com/.

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]